熱門資訊> 正文

Purple Biotech GAAP EPADS of -$0.86

2025-11-14 21:12

Purple Biotech(PPBT) 0

Purple Biotech press release (PPBT): Q3 GAAP EPADS of -$0.86.
Cash position of $10.5 million as of September 30, 2025, with an anticipated cash runway into the first half of 2027, supporting the development of our CAPTN-3 technology platform through significant milestones.

More on Purple Biotech

Purple Biotech announces receipt of Nasdaq minimum bid price notification
Purple Biotech prices $6M public offering, $12M potential via warrants; shares down
Seeking Alpha’s Quant Rating on Purple Biotech
Historical earnings data for Purple Biotech
Financial information for Purple Biotech

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。